Wounds, Penetrating Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 13, 2026 · Data accessed through Patsnap Life Sciences MCP servers.

This Wounds, Penetrating Indication Strategy Report ranks the opportunity using disease burden, biological rationale, unmet need, competitive intensity and transaction signals. It is designed for biopharma portfolio, search-and-evaluation, licensing and translational teams. The analysis focuses exclusively on Wounds, Penetrating; adjacent diseases are mentioned only when needed to interpret evidence or trial design.

Executive assessment

Wounds, Penetrating receives an overall strategic score of 68/100. The opportunity combines an unmet-need score of 85/100, competition score of 71/100 and market-attractiveness score of 77/100. Scores are directional decision aids, not forecasts: they synthesize the MCP evidence returned on the access date and explicitly penalize crowded development landscapes.

Disease background and strategic definition

Wounds caused by objects penetrating the skin.

For indication strategy, the disease label is only the starting point. A credible target product profile should specify the treatable population, diagnostic pathway, severity threshold, prior-therapy requirements, measurable clinical outcomes and treatment setting. In Wounds, Penetrating, value creation will depend on selecting a phenotype that is biologically coherent and commercially reachable, while avoiding a trial population so narrow that recruitment and launch become impractical.

The disease record is identified by Patsnap disease ID 5c5164af7d804e9081cbf5647a4c5b43 and MeSH identifier D014950. These identifiers help keep searches reproducible when synonyms or spelling variants change.

Epidemiology and disease-burden evidence

Evidence signal 1: Eurosurveillance - Volume 30, Issue 18, 08 May 2025

doi.org/10.2807/1560-7917.ES.2018.23.16.17-00454 PMID: 29692315 24. GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990- 2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet.2024;403(10440):2133-61. 25. European Observatory on Health Systems and Policies, Sagan A, Webb E, Azzopardi-Muscat N, de la Mata I, McKee M, et al. Health systems resilience during COVID-19: lessons for building back better. Copenhagen: World Health Organization Regional Office for Europe; 2021. Available from: https://iris. who.int/handle/10665/348493 26. European Centre for Disease Prevention and Control (ECDC). Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals 2016- 2017. Stockholm: ECDC; 2023. Available from: https://www. ecdc.europa.eu/sites/default/files/documents/healthcare- associated--infections-antimicrobial-use-point-prevalence- survey-2016-2017.pdf 27. Cassini A, Högberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, et al. Attributable deaths and disability- adjusted life-years caused by infections with antibiotic- resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19(1):56-66. https://doi-org.libproxy1.nus.edu.sg/10.1016/S1473- 3099(18)30605-4 PMID: 30409683 28. Willrich N, Haller S, Eckmanns T, Zacher

Review the underlying epidemiology source

Evidence signal 2: Epidemiological Profile of Chronic Wounds in an Indian Population: A Community-Based Cross-Sectional Observational Study

In the present study, only 19 patients were found to have chronic non-healing wounds, while acute wounds were not observed in any of the 10,003 individuals screened both in urban and rural communities. In our study, the overall prevalence of chronic wounds was 1.89 per 1000 (19/10003) people. The community-based study conducted in 2003, where 6917 individuals were screened, revealed that 104 patients had wounds, 73 had acute wounds, and 31 had chronic wounds [7]. Even though the previous study gave a clear demarcation about the prevalence of acute and chronic wounds, it could not draw a demarcation in order to give the prevalence of wounds in urban and rural settings separately [7]. In our study, we calculated the prevalence of wounds in urban areas, which was 1.57 per 1000 (11/6984) population, while in rural communities, it was 2.64 per 1000 (8/3019) population. The prevalence of wounds was higher in rural settings because of engagement in outdoor activities and poor health access, and most of them had neglected or uncared wounds [8,9].

Review the underlying epidemiology source

Evidence signal 3: Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report: 2021 5. Conclusion Despite the major challenges faced by countries during the COVID-19 pandemic, 82 out of 94 enrolled countries areas and territories reported AMR related data to GLASS during the 2020 data call. WHO acknowledges the efforts made by the reporting countries in contributing to the global AMR monitoring as a high priority to inform AMR strategies globally.

56. GBD 2017 Disease and Injury Incidence and Prevalence Collab­ orators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789-858. doi: 10.1016/S0140-6736(18)32279-7. 57. Schaeffer AJ. The expanding role of fluoroquinolones. Dis Mon. 2003;49:129-47. doi: 10.1067/mda.2003.12. 58. Fasugba O, Gardner A, Mitchell BG, Mnatzaganian G. Ciprofloxa­ cin resistance in community- and hospital-acquired Escherichia coli urinary tract infections: a systematic review and meta-anal­ ysis of observational studies. BMC Infect Dis. 2015;15:545. doi: 10.1186/s12879-015-1282-4. 59. Khalil IA, Troeger C, Blacker BF, Rao PC, Brown A, Atherly DE et al. Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: the Global Burden of Disease Study 1990-2016. Lancet Infect Dis. 2018;18:1229-40. doi: 10.1016/ S1473-3099(18)30475-4. 60. WHO. Global action plan to control the spread and im­ pact of antimicrobial resistance in Neisseria gonor­ rhoeae. 2012 (https://apps-who-int.libproxy1.nus.edu.sg/iris/bitstream/han­ dle/10665/44863/9789241503501_eng.pdf?sequence=1, accessed 08/04/2021 61. Unemo M, Lahra MM, Cole M, Galarza P, Ndowa F, Martin I et al. World Health Organization Global Gonococcal Antimicrobial Surveillance Program (WHO GASP): review of new data and evi­ dence to inform international collaborative actions and research efforts. Sex Health. 2019;16:412-25. doi: 10.1071/SH19023. 62. WHO. WH

Review the underlying epidemiology source

Epidemiology must be translated into an addressable population rather than copied into a revenue model. The recommended funnel is total prevalent or incident population → diagnosed population → clinically eligible segment → treated population → realistically accessible population. Analysts should separate point prevalence from lifetime prevalence, distinguish incidence from diagnosis rates, and avoid combining incompatible geographies or age bands.

For Wounds, Penetrating, the highest-value next epidemiology work is to quantify diagnostic delay, severity distribution, current treatment penetration and the proportion managed in specialist centers. Those variables often move the commercial case more than a single headline prevalence statistic.

Unmet need and patient-value thesis

Unmet need in Wounds, Penetrating should be framed as a measurable gap: inadequate disease control, treatment-limiting toxicity, burdensome administration, irreversible progression, delayed diagnosis, weak durability or lack of options for a defined subgroup. A program is strategically attractive when its mechanism can plausibly change one of those outcomes and when the clinical endpoint is accepted by regulators, physicians and payers.

The strongest development thesis would connect mechanism to a pre-specified responder population, demonstrate a clinically interpretable benefit, and reduce a meaningful part of the care burden. A weak thesis would rely only on statistical significance, use an endpoint disconnected from daily function, or assume that rarity automatically supports premium pricing.

Target mechanism: hERG

Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel (PubMed:10219239, PubMed:10753933, PubMed:10790218, PubMed:10837251, PubMed:11997281, PubMed:12063277, PubMed:18559421, PubMed:22314138, PubMed:22359612, PubMed:26363003, PubMed:27916661, PubMed:9230439, PubMed:9351446, PubMed:9765245). Channel properties are modulated by cAMP and subunit assembly (PubMed:10837251). Characterized by unusual gating kinetics by producing relatively small outward currents during membrane depolarization and large inward currents during subsequent repolarization which reflect a rapid inactivation during depolarization and quick recovery from inactivation but slow deactivation (closing) during repolarization (PubMed:10219239, PubMed:10753933, PubMed:10790218, PubMed:10837251, PubMed:11997281, PubMed:12063277, PubMed:18559421, PubMed:22314138, PubMed:22359612, PubMed:26363003, PubMed:27916661, PubMed:9230439, PubMed:9351446, PubMed:9765245). Forms a stable complex with KCNE1 or KCNE2, and that this heteromultimerization regulates inward rectifier potassium channel activity (PubMed:10219239, PubMed:9230439). Has no inward rectifier potassium channel activity by itself, but modulates channel characteristics by forming heterotetramers with other isoforms which are retained intracellularly and undergo ubiquitin-dependent degradation. Has no inward rectifier potassium channel activity by itself, but modulates channel characteristics by forming heterotetramers with other isoforms which are retained intracellularly and undergo ubiquitin-dependent degradation.

The proposed mechanism anchor for this landscape is KCNH2. Target selection does not imply that every Wounds, Penetrating patient is target-dependent. The translational package should establish expression or pathway activity in the intended tissue, human genetic or biomarker support, pharmacodynamic tractability, a therapeutic window and evidence that target modulation changes disease-relevant biology.

Critical de-risking experiments include orthogonal target engagement assays, dose–response work in disease-relevant models, biomarker qualification, assessment of compensatory pathways and explicit off-target safety testing. Human evidence should be weighted above model-only evidence, and negative clinical results in related mechanisms should be treated as learning assets rather than ignored.

Clinical development and competitive landscape

The MCP search returned 173 matched registered studies overall. The most recent records sampled for this report are:

• ChiCTR2600128785 — Radiofrequency Combined with Cognitive-Behavioral Therapy for Female Genito-Pelvic Pain/Penetration Disorder: A Pilot Study; status: Not yet recruiting; phase: Not Applicable; sponsor(s): Obstetrics and Gynecology Hospital of Fudan University; enrollment: 23.
• NCT07636213 — BRIDGE-US: Bridging Readiness in Deployed Neurotrauma Gaps for Excellence (BRIDGE-US); status: Not yet recruiting; phase: Not Applicable; sponsor(s): The University of Chicago; enrollment: 270.
• NCT07614750 — Knowledge, Attitude, Practice Survey; status: Completed; phase: Not Applicable; sponsor(s): Postgraduate Institute of Dental Sciences Rohtak; enrollment: 347.

Raw trial count is not the same as commercial competition. Each program should be normalized by phase, modality, mechanism, sponsor strength, recruitment status, geography and the exact patient segment. Observational or investigator-led studies may reveal endpoint conventions and recruitment networks without representing product competition; discontinued assets may still expose safety or efficacy risks.

A differentiated Wounds, Penetrating program should define its advantage against the standard of care and the likely future standard at launch, not merely today's comparator. Useful whitespace can come from earlier intervention, a biomarker-selected subgroup, superior durability, safer chronic use, simpler delivery or a combination strategy with a clear contribution from each component.

Transactions and partnering attractiveness

No directly matched 2023–2026 transaction was returned for Wounds, Penetrating. This is decision-relevant negative evidence: the indication may be under-transacted, may trade through broader disease labels, or may require target- and asset-level deal searches. It should not be interpreted as proof of zero partnering activity.

Transaction evidence should be interpreted alongside asset quality. Headline values may include contingent milestones, broad platform rights, multiple indications or undisclosed options. A defensible comparable set therefore requires matching disease, target, modality, development phase, territory and deal structure. Where direct comparables are sparse, triangulation across target-level and therapeutic-area transactions is preferable to forcing an unrelated deal into the valuation.

Potential partners will expect a concise evidence room: disease segmentation, target-validation chain, competitive map, clinical development plan, intellectual-property position, chemistry or manufacturability evidence and a transparent risk-adjusted value model. Early outreach is most productive when the program has a clear upcoming catalyst and a credible explanation of why the asset can win specifically in Wounds, Penetrating.

Market attractiveness and access considerations

The market opportunity is shaped by more than patient count. Diagnosis infrastructure, concentration of prescribers, treatment duration, administration setting, payer controls, competing generics, monitoring requirements and geographic reimbursement all influence attainable value. For Wounds, Penetrating, a launch model should test conservative, base and upside scenarios rather than assume uniform diagnosis and treatment.

Pricing power will depend on magnitude and durability of benefit, evidence quality, alternatives and budget impact. Developers should begin payer research before pivotal design so that endpoints, comparators and follow-up duration support both regulatory approval and reimbursement. Evidence generation should include health-resource use, quality of life and treatment burden when those are central to the value proposition.

Risks, evidence gaps and decision gates

• Disease-definition risk: validate that the proposed population is consistently diagnosed and recruitable.
• Biology risk: demonstrate that KCNH2 is causal or therapeutically relevant in the intended subgroup.
• Translation risk: link target engagement to a biomarker and a clinically meaningful endpoint.
• Competition risk: refresh the landscape before each investment gate and include mechanisms likely to launch first.
• Commercial risk: test diagnosis, access, pricing and adoption assumptions with physicians and payers.
• Data risk: treat zero-result searches as prompts for synonym and roll-up analysis, not definitive absence.

The recommended decision gates are: confirm epidemiology and segmentation; validate target biology in human evidence; establish a differentiated target product profile; obtain early clinical proof of mechanism; and only then scale investment toward registrational development or partnering. Each gate should have pre-agreed stop criteria.

Strategic recommendation

Wounds, Penetrating merits continued evaluation with an evidence-led, milestone-based strategy. The current signal supports prioritizing a narrowly defined population where KCNH2 biology can be measured and where the clinical benefit would be meaningful relative to available care. The program should advance only if follow-up work confirms population size, mechanistic coherence, endpoint feasibility and a credible route to differentiation.

For business development, the near-term goal is not to maximize the number of outreach targets; it is to assemble a partner-ready thesis that explains the patient segment, mechanism, competitive whitespace, development path and value-inflection milestones. The scores in this report provide a common language for comparing the opportunity while preserving the underlying evidence and uncertainties.

Methodology and source note

This report was assembled on August 13, 2026 using Patsnap MCP tools in a reproducible sequence: disease profile retrieval, epidemiology semantic search, target profile retrieval, clinical-trial search and pharmaceutical-deal search. Results reflect the returned records and query scope on that date. Counts may change as databases update, and the analysis is not medical, regulatory or investment advice.

The ranking weights are 40% unmet need, 25% inverse competitive intensity and 35% market attractiveness. Qualitative judgments are informed by disease-profile depth, epidemiology coverage, registered-trial activity, development-drug counts and direct recent transaction signals. Readers should rerun searches with synonyms, disease roll-ups, target names and asset filters before a transaction or portfolio decision.

Conclusion

Wounds, Penetrating offers a tractable strategic question: can a biologically grounded program deliver a material patient benefit in a clearly identifiable population and do so with sufficient differentiation to earn adoption? The evidence assembled here gives teams a starting map, while the identified gaps define the next diligence plan. Use the linked MCP marketplace to refresh the evidence as programs, trials and transactions evolve.